Strategy
Vaxcyte Moves to Raise $1 Billion After the Close, Hours After Its Phase 3 Vaccine Result
The company launched a $500 million equity and pre-funded warrant offering alongside $500 million of convertible notes due 2032, after shares closed up 30.7% on trial data.
AF
By Anna Ferreira
Oct 6, 2026 · 2 min read
Vaxcyte moved to raise about $1 billion in the hours after Monday's close, launching two simultaneous offerings on the same day it reported that its lead pneumococcal vaccine candidate met every primary endpoint in a pivotal adult trial.
Discussion (0)
Sign in to join the discussion.
Loading comments…
AF
Anna Ferreira
Senior Correspondent, Corporate Strategy
Anna Ferreira writes for Corporate Insider Inc.